BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3340-3348

  Bednarz, Natalia ^a,b   Eltze, Elke ^c   Semjonow, Axel ^d   Rink, Michael ^a   Andreas, Antje ^a   Mulder, Lennart ^e   Hannemann, Juliane ^a   Fisch, Margit ^a   Pantel, Klaus ^a   Weier, Heinz Ulrich G ^f   Bielawski, Krzysztof P ^b   Brandt, Burkhard ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GDA SK   (Poland)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN; VIMENTIN;

ADULT; AGED; ALLELE; ARTICLE; BIOCHEMISTRY; BLOOD; CANCER GROWTH; CELL SUBPOPULATION; CHROMOSOME 17; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOSS; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR SUPPRESSOR GENE;

AGED; CHROMOSOMES, HUMAN, PAIR 17; DISEASE PROGRESSION; GENE DELETION; GENE DOSAGE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 77954233490     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0150     Document Type: Article

References (33)

1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
2. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9.
3. Schmidt H, DeAngelis G, Eltze E, Grockel I, Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 2006;66:8959-65.
4. Boulton S. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006;34:633-45.
5. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
6. Beger C, Ramadani M, Meyer S, et al. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. Clin Cancer Res 2004;10:3780-7.
7. Grabsch H, Dattani M, Barker L, et al. Expression of DBA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006;12:1494-500.
8. Xing D, Scangas G, Nitta M, et al. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 2009;69:8231-5.
9. Liede A, Karlan BY, Narod SA. Cancer risk for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004;4:735-42. (Pubitemid 41095079)
10. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-7.
11. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009;15:1112-20.
12. Gao X, Zacharek A, Salkowski A, et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995;55:1002-5.
13. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumours from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-7.
14. Uchida T, Wang C, Sato T, et al. BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer 1999;84:19-23.
15. Watanabe M, Shiraishi T, Muneyuki T, et al. Allelic loss and microsatellite instability in prostate cancers in Japan. Oncology 1998;55:569-74.
16. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005;206:451-7.
17. Brandt B, Griwatz C. Two-layer buoyant density centrifugation gradient for enrichement of prostate-derived cells and cell clusters from peripheral blood. Clin Chem 1996;42:1881-2.
18. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
19. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003;100:15077-82.
20. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008;32:503-18.
21. Herz HM, Woodfield SE, Chen Z, Bolduc C, Bergmann A. Common and distinct properties of ESCRT-II components in Drosophila. PLoS One 2009;4:e4165.
22. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shown the PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85.
23. Wang S, et al. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 2006;5:1480-5.
24. Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
25. Xu X, Gammon MD, Zhang Y, et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009;115:397-404.
26. Press JZ, de Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
27. Staff S, Isola J, Tanner M. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res 2003;63:4978-83. (Pubitemid 37022634)
28. Yasmeen A, Liu W, Dekhil H, et al. BRCA1 mutations contribute to cell motility and invasion by affecting its main regulators. Cell Cycle 2008;23:3781-3.
29. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S. BRCA1 modulates malignant cell behaviour, the expression of surviving and chemosensitivity in human breast cancer cells. Int J Cancer 2009;125:2820-8.
30. Lang SH, Hyde C, Reid IN, et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002;52:253-63.
31. Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008;26:571-7.
32. Dubrovska A, Sungeun K, Salamone RJ, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad SciUS A 2009;106:268-73.
33. Plo I, Laulier C, Gauthier L, Lebrun F, Calvo F, Lopez BS. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 2008;68:9404-12.